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Abstract
Previous studies of the effects of coenzyme Q10 and minocycline on mouse models of Huntington’s disease have produced
conflicting results regarding their efficacy in behavioral tests. Using our recently published best practices for husbandry and
testing for mouse models of Huntington’s disease, we report that neither coenzyme Q10 nor minocycline had significant
beneficial effects on measures of motor function, general health (open field, rotarod, grip strength, rearing-climbing, body
weight and survival) in the R6/2 mouse model. The higher doses of minocycline, on the contrary, reduced survival. We were
thus unable to confirm the previously reported benefits for these two drugs, and we discuss potential reasons for these
discrepancies, such as the effects of husbandry and nutrition.
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Introduction
Since the identification of the mutation underlying Huntington’s
disease (HD) much progress has been made in uncovering its
complex molecular pathophysiology [1,2]. However, despite the
apparent simplicity of the mutation, a large number of cellular
pathways, and molecular targets, have been implicated in the
disease pathology [3]. As HD researchers identify more candidate
targets and potentially therapeutic compounds, prioritizing
projects to move towards clinical trials becomes even more
daunting [4].
Until now, HD clinical trials have identified agents that provide
symptomatic relief, including selective serotonin reuptake inhib-
itors for depressive symptoms, benzodiazepines for anxiety,
atypical antipsychotics for psychotic symptoms, and, most
recently, tetrabenazine for chorea (see review in [5,6].
Several clinical trials have also evaluated compounds for their
ability to alter disease progression, including riluzole, ethyl-
eicosapentanoic acid, creatine, coenzyme Q10 (CoQ10), lamo-
trigine, amantadine and memantine. These compounds show
some promise in reducing chorea and motor symptoms. In terms
of treatments altering disease progression, several compounds
including riluzole, ethyl-eicosapentanoic acid, creatine, CoQ10,
lamotrigine, amantadine and memantine have been studied in
clinical trials and also shown some relief (see reviews in [5,7].
CoQ10 is an endogenous substance present in the mitochon-
drial membrane that acts as an electron acceptor to help generate
energy by shuttling electrons during oxidative phosphorylation. It
also acts as an antioxidant in both mitochondrial and lipid
membranes [8]. While CoQ10 has poor oral bioavailability and
brain penetration in both rodents and humans [9], several studies
showed significantly increased levels of CoQ10 in plasma and
brain following oral supplementation [10,11,12]. In various studies
using different HD rodent models, CoQ10 extended survival and
improved motor behavior, gross brain morphology, aggregate
load, ATP levels and indicators of oxidative damage
[11,13,14,15,16,17,18]. Beneficial effects have also been reported
for other neurodegenerative models, such as the MPTP model of
Parkinson’s disorder [19].
Minocycline is a second-generation tetracycline antibiotic,
which readily crosses the blood-brain barrier [20]. Minocycline
has been reported to have effects on caspase activation,
neuroinflammation, glutamate excitotoxicity, free radical-induced
toxicity and aggregation, all processes implicated in HD
pathophysiology [21,22,23,24,25,26]. Using behavioral endpoints,
two studies reported improvement in rotarod performance and
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survival in R6/2 mice [15,25] although others reported either
negative or lack of effects in R6/2 [26], no effects in the N171-
82Q model [27] and toxicity in the 3-nitroproprionic acid HD
model [28].
Given the disparity of results concerning minocycline in the
preclinical realm, and the interest in both these compounds in the
clinical arena, we chose to reassess their preclinical effects in HD
using the R6/2 model. This widely used mouse model recapitu-
lates many of the key features of human HD. In this paper we
apply our recently published best practices for husbandry and
testing [29] to assess the putative therapeutic effects of CoQ10 and
minocycline in R6/2. Our results suggest that neither compound
has a robust therapeutic effect in this HD model and that,
moreover, minocycline can produce negative effects.
Materials and Methods
Subjects
Animal care was in accordance with the United States Public
Health Service Guide for the Care and Use of Laboratory Animals, and
procedures were approved by the Institutional Animal Care and
Use Committee at Psychogenics Inc.. R6/2 transgenic mice
expressing the N-terminal region of a mutant human huntingtin
gene [30] and wild type (WT) littermates were generated by
crossing ovarian-transplanted females (from R6/2 CBAxC57Bl/6
female donors) with CBAxC57Bl/6 F1 WT males. Genotype was
determined at 15 days of age by PCR of tail snips [31]. Laragen
Inc. (USA) measured CAG repeat lengths. All CAG repeat
numbers reported here are those determined directly by
Genemapper software. Mice were weaned at approximately 3
weeks of age and behavioral tests were performed at 4, 6, 8 and 12
weeks of age, unless otherwise specified.
Husbandry
Mice were group-housed (4–5/cage) in shoebox cages with
wood shavings and a filter top. The environment was enriched
with a play tunnel, shredded paper, and a plastic bone. Breeder
animals also received cotton nestlets and igloos, instead of play
tunnels. Food and water were available ad libitum. R6/2 and
corresponding WT mice in the minocycline studies received wet
powdered food placed inside a cup on the floor of the cage; this
additional food was replaced fresh daily and was provided starting
at the time of weaning. All mice in the CoQ10 studies received
CoQ10-supplemented pelleted food on the floor of the cage. To
ensure that calculated doses were obtained, these mice did not
received additional wet mush. Temperature (68–76uC), humidity
(30–70%) and the light-dark cycle (6:00–18:00 EST) were
controlled and monitored daily. Litters of three or less mice were
not used. Mice from multiple litters (at least three) were used for
each treatment group (n= 20–40; equally divided between
genders). A semi-randomized selection process was performed in
which mice were grouped matching for body weight and CAG
repeat length (mutants only). There were thus, no statistical
differences between mutant mice assigned to the different groups
within each study. Animals that presented abnormalities such as
hydrocephaly, failure to thrive, missing limbs and/or were
abnormally small (runts) were excluded from the experimental
groups. Body weights were recorded weekly (with the exception of
the study with CoQ10 at 0.2%, in which measures were taken
biweekly during testing weeks and the study with minocycline
5 mg/kg i.p. when measures were taken three times a week).
Cages and animals were carefully manipulated to avoid excess
stress or stimulation that may trigger seizures.
Experimental Procedures
Animals were assigned to the different treatment groups in a
semi-randomized fashion, which ensured that there were no
significant differences in body weight before the beginning of the
testing or of CAG repeat lengths amongst the different treatment
groups. The behavioral assays listed below were performed at 4, 6,
8, 10 and 12 weeks of age, unless otherwise noted. Researchers
were blind to treatment during experiment testing and data
collection. A single investigator conducted each behavioral test.
Behavioral testing was always conducted 1 h after lights on and
1 h before lights off.
Survival. All mouse cages were examined daily in order to
determine lifespan. Mice were noted as dead when they no longer
had a heartbeat. Mice were euthanized if found moribund, as
defined by lack of movement even after prodding, and/or lying on
side and lack of righting reflex.
Rotarod. Mice were tested over three consecutive days at 4,
6, 8 and 12 weeks of age using an accelerating rotarod assay
(Menalled et al., 2009). Each daily session started in the morning
hours, between 9–11 am, and included four trials. The first trial
was a training trial of 5 min at 4 RPM on the rotarod apparatus
(AccuScan, OH). One hour later, the animals were tested for three
consecutive accelerating trials of 5 min with the speed changing
from 4 to 40 RPM and an inter-trial interval of at least 30 min.
The latency to fall from the rod was recorded. Mice remaining on
the rod for more than 300 s were removed and their time scored
as 300 s. In less than 1% of the trials, a fecal bolus dropping broke
the infrared (IR) beam and terminated the trial prematurely. On
these occasions, the trial was restarted for that particular animal
and the time to fall was recalculated; these data were removed for
analysis for that time point only. To minimize experimenter
variability, a single individual performed all tests.
Open field. This test was performed during the light phase of
the light cycle at 4, 6, 8 and 12 weeks of age. Activity chambers
(Med Associates Inc, St Albans, VT; 27627620.3 cm) were
equipped with infrared beams. Mice were placed in the center of
the chamber and their behavior was recorded for 30 min.
Quantitative analyses were performed on the following three
dependent measures: total locomotion, locomotion in the center of
the open field, and rearing rate in the center.
Rearing-climbing. To test rearing and climbing abilities, a
metal-wire mesh pencil holder was inverted over mice placed on a
surface. Climbing was recorded in 5 min-testing sessions that were
videotaped for analysis.
Grip strength. This test was performed at 4, 6, 8, 10 and 12
weeks of age. However, only data corresponding to the 12-week
time point are reported because no deficiencies in grip strength
due to genotype were detected prior to this age. To measure
forelimb grip strength, a mouse was held by the tail and lowered
towards the apparatus (Ugo Basile, Italy) until it grabbed a handle
with both front paws. Mice were gently pulled back until they
released their grip from the handle. Each session consisted of five
consecutive trials. The equipment automatically measures the
grams of force required to pry the mouse from the handle.
Animals receiving CoQ10 were also evaluated in the prepulse
inhibition of startle test. (No drug effects found. Data not shown.)
Treatments
Treatments were started at 4 weeks of age 63 days to maximize
the opportunity to detect any treatment effects. Drugs sharing the
same vehicle or control treatment were run together. Groups of
10–21 animals per gender per genotype were used in each
treatment group.
Minocycline & CoQ10, R6/2 Mice
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Experiment 1. CoQ10 0.2%: Thirty-eight to 40 mice per
genotype (19–20 per gender) were used in each treatment group.
The mean CAG repeat length for untreated animals was
125.5861.00 and for treated animals 125.8560.95. Animals
were placed on either an unsupplemented diet or a diet
supplemented with 0.2% CoQ10 (Health Weight Products Inc.;
Clackmas, Oregon), corresponding to a daily dose of 400 mg/kg
assuming a 20 g mouse eats 4 g per day. Both diets were delivered
in the form of pelleted mouse chow (Purina Test Diets, Richmond,
IN) as described elsewhere [13,15].
Experiment 2. CoQ10 0.6% with gamma-cyclodextrin: Twenty
mice per genotype (10 per gender) were placed on a diet
supplemented with 0.6% CoQ10 with gamma-cyclodextrin
(Tishcon, Westbury, NY) containing 20% CoQ10 and 80%
gamma-cyclodextrin. This corresponds to a daily dose of
1200 mg/kg. Twenty mice per genotype (9–11 per gender) were
placed on an unsupplemented diet containing only gamma-
cyclodextrin (2.5%). The mean CAG repeat length for
unsupplemented diet group was 12460.74 and for the treated
animals 123.160.59. Both diets were made into pelleted mouse
chow (Purina Test Diets, Richmond, NY).
Experiment 3. Intraperitoneal minocycline (5 mg/kg): Sixteen to
22 mice per genotype (8–11 mice per gender) received daily
intraperitoneal injections of either saline or minocycline (5 mg/kg,
Sigma Aldrich, St. Louis, MO) starting at 6 weeks of age. The
mean CAG repeat length of vehicle-treated animals was
108.5660.67 and of minocycline-treated animals 109.1160.72.
Daily injection volume was 5 ml/kg. Minocycline solutions were
prepared daily to ensure compound stability. Dosage and
administration were as described elsewhere [25]. To avoid acute
effects, all behavioral testing was conducted at least 3 hours after
injections.
Experiment 4. Oral minocycline 0.1% and 0.375%: Twenty two
to 24 mice (11–12 per gender) per genotype received wet food
supplemented or unsupplemented with minocycline (0.1% or
0.375%; corresponding to 200 and 750 mg/kg per day,
respectively, Sigma-Aldrich, St. Louis, MO). The mean CAG
repeat length of vehicle-treated animals was 122.9160.62, of
animals treated with 0.1% minocycline 125.1760.69, and of
animals treated with 0.375% minocycline 124.0460.91.
Minocycline supplemented food was prepared daily by mixing
powdered minocycline with dry powdered food. Water was added
to the mixture at a 1:1 weight ratio. The unsupplemented control
diet was also made daily in a similar manner. The resulting mush
was placed in an open plastic container on the floor of each cage.
Pelleted dry food was not given to these animals to ensure they
received the complete minocycline dose.
CoQ10 measurements. Measurements were made by LC/
MS/MS analytical methodology. The system consisted of a
Phenomenex Polar RP column, 5062.1 mm id, 4 mm. The
Mobile Phase was 100% methanol, isocratic with a flow rate of
400 mL/min and a total run time of 4.0 min. The injection volume
was 40 mL. For MS, the system consisted of a PE Sciex API 4000
Triple Quadrupole with a heated nebulizer interface. Temperature
was 400uC. Standards and quality control samples were prepared in
neat matrix. Stock solutions of CoQ were prepared in ethanol.
Standards were prepared by serial dilution in 5:1, n-propanol:water
at 2500, 1000, 500, 100, 50, 10, 5, 1 and 0.5 ng/ml. Brain samples
were homogenized using a Virsonic 100 ultrasonic homogenizer.
Each sample was first weighed and then placed into a 5 ml test tube.
An appropriate amount of 20:80, methanol:water was added to
make a 1 g/4 ml mixture. These samples were then homogenized
and the final volumes were measured. All samples were then stored
at 280uC pending analysis. Plasma and brain samples were
prepared by precipitation with n-propanol. To a 1.7 ml centrifuge
tube, 50 ml of appropriate sample was added. To each tube, 12.5 ml
of a 2 mg/ml solution of 1,4 benzoquinone was added, capped,
vortexed, and left to stand for ten minutes. Addition of 1,4
benzoquinone oxidizes all CoQ10 in the sample to the fully oxidized
state, allowing for the determination of total CoQ10 in each sample.
To each sample, 250 ml of n-propanol was then added. The samples
were vortexed briefly, and then centrifuged at 13000 rpm for ten
minutes. A 100 ml aliquot of each sample was then transferred to an
HPLC vial for analysis.
Minocycline measurements. Minocycline levels in brain
and plasma were determined as described elsewhere [26]. Briefly,
WT and R6/2 mice (n = 3 per gender, per genotype, per
treatment) were fed either minocycline-supplemented powdered
food or control chow for 3–4 weeks before collecting tissue.
Animals were euthanized with CO2 and blood was collected from
the chest cavity before dissecting the brain. The blood collection
tube, containing EDTA, was gently inverted immediately after
sample collection. The samples were then placed on ice and spun
at 5000 RPM for 15 min at 4uC in a refrigerated centrifuge. The
plasma was then pipetted out of the sample collection tube. Brains
were dissected and immediately frozen in powdered dry ice. Levels
of minocycline were assessed as described by [32]. In brief, brains
were homogenized, and centrifuged for 1 hour at 10,000g at 4uC.
The supernatant was stored at 280uC for HPLC analysis.
Reverse-phase HPLC was performed using a Waters 600E
solvent delivery module and a Waters 484 UV detector.
Samples were analyzed on a Hypersil H5ODS column (15cm
4.6mm, Hichrom, Berkshire, UK) by isocratic elution. The
minocycline concentrations were calculated against a standard
curve made by adding in known concentrations of minocycline to
brain or plasma samples and extracting [33].
Statistics
An alpha level of 0.05 was selected for all inferential statistics.
The repeated measures analyses were carried out with SAS (SAS
Institute Inc.) using Mixed Effect Model (also known as Mixed
ANOVA Model). These analyses are based on likelihood
estimation, which is more robust to missing values than moment
estimation. The models were fitted using the procedure PROC
MIXED [34]. Slight variations of those models were tested and the
best model based on the AIC/BIC criteria [35] was selected. In
the present study, treatment was considered the most important
factor in the model. Gender was included as a factor in the model
when it shows a significant interaction with treatment. Time bins
and age were considered as correlated measures.
Genotypic differences were analyzed separately from treatment
and in all cases matched published results showing progressive
deficits in the R6/2 mice in all measures shown [36,37].
Therefore, genotype as a factor was not included in any of the
statistical models and only data from the mutant animals were
included in the analysis. The treatment effect on the WT animals,
when available, was included in the figures and is discussed for
comparison purposes only. As differences in PK/PD between
genotypes could change the effects of the drugs, we compared the
levels of drugs in brain and plasma of treated versus untreated
groups and treated mutants versus WT mice. Significant
interactions with treatment were analyzed with simple main effect
test followed by Fisher LSD where indicated.
For the rearing climbing test, the latency to climb was
categorized as climbing or not climbing. Differences between
treatments were analyzed with a Chi Square at each age
separately. Gender differences were not apparent so data were
pooled across genders.
Minocycline & CoQ10, R6/2 Mice
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Survival data were analyzed with Kaplan-Meier analysis (with
the p values derived from the Mantel-Cox Log-rank statistic).
Power analyses showed that, fixing alpha at 0.05, effect size at
30% and sample size at either 20 or 40 mice per group, we
obtained power .0.80/0.97 (n= 20/n=40) for rearing in the
open field ($12 weeks of age), $0.89/0.99 for body weight ($14
weeks of age) and $0.93/0.99 for rotarod ($12 weeks of age), grip
strength and locomotion were the less robust measures with power
of 0.66/0.90 for grip strength and 0.19/0.29 for locomotion in the
open field ($12 weeks for both parameters). The open field thus
should be used to obtain rearing measures, rather than locomotion
(although this endpoint is robust at later ages [29]. The climbing
behavior in the rearing-climbing test show high power (..87) at
both sample sizes ($12 weeks of age).
Results
Experiment 1
CoQ10 at 0.2%. We tested the effects of oral administration of
0.2% CoQ10 on the survival, weight and behavior of R6/2 mice
and measured CoQ10 concentrations in plasma. This dose was
chosen based on the study by Ferrante and colleagues, in which
CoQ10’s therapeutic effects in R6/2 mice were first described [13].
As shown in Fig 1, no beneficial effects of coenzyme Q in the
R6/2 mice were detected in survival, body weight, latency to fall
from the rotarod, total rearing frequency in the center of the open
field, and climbing, in the rearing-climbing test. Non-progressive
transient deleterious effects were observed in the total distance
traveled in the open field and grip strength.
Figure 1. Effect of the administration of 0.2% of CoQ10 in food in R6/2 mice. WT mice received unsupplemented diet (UD) and R6/2 mice
received either UD or 0.2% CoQ10. There were no significant treatment effects on survival (A), body weight (B) or rotarod (C: latency to fall).
Deleterious effects of 0.2% CoQ10 were observed in the total distance traveled in the open field (D) at 4 and 12 weeks of age, mainly in the first 5 min
of the session (treatment6age interaction: F(3,213) = 7.5, p,0.0001; treatment6session time interaction: F(5,375) = 2.5, p,0.04; simple main effects:
p,0.05). There were no effects on the rearing frequency in the open field (E); CoQ10 impaired grip strength (F) of female mice at 12 weeks of age
(treatment6gender interaction (F(1,76) = 11.3, p,0.002, simple main effects: p,0.001) and decreased the number of mice that climbed in the rearing
climbing test (G, p,0.04).
doi:10.1371/journal.pone.0009793.g001
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Experiment 2
CoQ10 at 0.6%. Smith et al. reported that high-dose CoQ10
(0.5%) significantly improved survival and the behavioral
phenotype of R6/2 mice, delaying weight loss, motor deficits,
and loss of grip strength. In addition, the study suggested that use
of the HydroQSorb formulation (Tishcon Corp), is effective at a
lower concentration [14]. We administered 0.6% CoQ10 in the
HydroQSorb formulation and measured plasma and brain
CoQ10 levels, in addition to the behavioral assessment.
As shown in Fig. 2, CoQ10 did not have beneficial effects on
survival, rotarod performance, grip strength performance and
climbing although transiently decreased body weight, locomotor
activity and rearing in R6/2 mice with no effects in WT.
Plasma levels of CoQ10 were higher in treated than in
untreated mice, regardless of the genotype (Table 1). Treated
R6/2 mice had higher plasma CoQ10 levels than treated WT
mice. Concentrations were higher in females than male mice. We
also found a smaller but significant increase in brain CoQ10 levels
in treated mice as compared to untreated mice, independent of
gender and genotype.
Experiment 3
Minocycline at 5mg/kg. In this experiment, minocycline
was injected daily, i.p., at 5 mg/kg, a dose reported to ameliorate
the HD phenotype in R6/2 mice by Chen et al. [25].
As shown in Fig. 3, minocycline did not affect survival, grip
strength, rotarod, or climbing although it did transiently increased
body weight and locomotor activity in R6/2 mice. Rearing
frequency was transiently impaired in female but improved in
male R6/2 mice (see legend of figure 3 for statistical details). In the
Figure 2. Effect of the administration of 0.6% of CoQ10 in food in R6/2 mice.WT mice and R6/2 mice were fed with a diet with HydroQsorb
(HQD) alone or with 0.6% CoQ10 in HQD. There was no treatment effect on survival (A). CoQ10 significantly decreased the body weight (B) of R6/2
males between 6 and 10 weeks of age (treatment6age6gender interaction: F(22,330) = 4.1, p,0.0001; simple main effects: ps,0.05). There were no
effects of treatment on the latency to fall from the rotarod (C). In mutant females, CoQ10 diminished locomotor activity in the open field (D). Treated
R6/2 females were significantly hypoactive at 4 weeks (0–5 min), 6 weeks (last 10 min), at 12 weeks of age (20 to 25 min; treatment6gender
interaction: F(1,35) = 6.7, p,0.02; simple main effects: p,0.007; treatment6age6time interaction: F(30,460) = 3.4, p,0.0001; simple main effects:
ps,0.05). R6/2 treated mice reared significantly less in the open field (E) at 6 weeks of age compared with untreated mutant mice (treatment6age
interaction: F(3,92) = 3.2, p,0.03; simple main effects: p,0.035). There were no treatment effects on either grip strength (F) or in the rearing climbing
test (G). CoQ10 had no effects in WT mice (A–F).
doi:10.1371/journal.pone.0009793.g002
Minocycline & CoQ10, R6/2 Mice
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WT group, minocycline did not affect body weight, rotarod or grip
strength performance, but transiently impaired locomotion and
rearing.
Both WT and R6/2 mice treated with minocycline weeks had
detectable concentrations of the compound in both plasma and
brain. All minocycline concentrations were higher in wild type
mice than in R6/2 mice (Table 2)
Experiment 4
Minocycline at 0.1 and 0.375%. We also tested two oral
doses of minocycline based on Smith et al’s study [26] in which higher
concentrations of plasma and brain minocycline were achieved as
compared to the daily i.p. injections of Chen et al’s study [25]. Smith
and colleagues reported an approximately 10-fold higher
concentration of minocycline in brain without ill effects using
1 mg/ml and 5 mg/ml oral minocycline (in the drinking water)
compared to a single-dose injection of 5 mg/kg. A single bolus dose is
unlikely to result in similar brain exposure compared to that achieved
in continuous treatment because of the 2-h plasma half-life of
minocycline in mice [38]. Based on these observations, we fed R6/2
and WT mice diets containing 0.1% or 0.375% minocycline
assuming that a 20 g mouse eats 4 g of food per day. This is
equivalent to doses of 1.3 mg/ml and 5 mg/ml in the drinking water,
respectively, assuming that a 20 g mouse drinks 3 ml of water/day.
In the R6/2 mice, as shown in Fig. 4, we observed a negative
effect on survival of both doses of minocycline. Whereas the low
dose transiently increased body weight and rearing, the high dose
reduced them. The 0.375% dose of minocycline had a minor and
transient beneficial effect on rotarod performance, and slightly
decreased the locomotor activity in the open field, while no effect
was detected in the low dose treated group. Although the 0.375%
dose of minocycline also decreased the rearing in male WT mice,
it had no effect on any other measure (see legend of figure 4 for
statistical details).
Table 2 shows minocycline concentrations in plasma and brain
after 44 days of treatment. In contrast to what was found in the
5 mg/kg i.p. dosing study, brain and plasma concentrations of
minocycline in R6/2 mice were significantly higher than in WT
mice treated with 0.375% of minocycline. Overall brain
concentrations, however, were lower than those reported by
Smith et al.: 14.5 mM (WT) and 15.5 mM (R6/2), at 1 mg/ml
(about equivalent to 0.08% in the food); and 18.7 mM (WT) and
20.5 mM (R6/2) at 5 mg/ml (0.375%).
Discussion
The goal of the present study was to test an optimized
husbandry and behavioral test battery for the evaluation of
candidate therapeutic compounds, and reassess with this battery,
two compounds tested in preclinical and clinical trials. Our results
indicate that high doses of CoQ10 did not ameliorate health,
motor, or behavioral symptoms or slow down progression in a
mouse model of HD. No dose of minocycline produced any
beneficial effects while the highest dose had a clear negative effect
on survival and other endpoint measures.
We have developed our drug screening assay to ensure that each
treatment group was as similar as possible in terms of biological
factors like CAG repeats, initial body weight, and litter size, in
order to minimize any potential confounding factors. In addition,
all these studies included only animals from healthy litters where
more than three pups were viable until weaning, to ensure that any
deficits observed cannot be attributed to extraneous factors. In
addition, in other studies under the same conditions, we did not
observe a clear phenotype indicating imminent death in the R6/2
mice. In particular, we have investigated whether widely used
criteria like loss of righting reflex or loss of response to tactile
stimulation correlated with death within a 24-hr period and could
not detect a relationship. Therefore, no surrogate endpoint for
euthanasia was available, in contrast to many other published
studies, and survival data reflects the animals’ death from natural
causes.
CoQ, nutrition and enrichment
Unlike a previous study reporting that HydroQsorb CoQ10
extends survival in R6/2 mice to a greater degree and at a lower
concentration than standard CoQ10 formulations [14], we found
that neither formulation showed efficacy even though doses were
similar to the ones previously used. Important differences between
the studies previously published and the results reported here
include animal husbandry conditions and criteria of euthanasia
(see above).
In the present study, plasma levels of mice receiving CoQ10
were 0.5 to 1.6 mg/ml, which is in line with other studies [19,39].
The brain levels we measured after treatment with CoQ10, 13.2–
14.2 mg/g, are also in line with other studies [10].
Differences in intake, drug metabolism and/or fat content might
have also impacted CoQ10 plasma levels achieved in R6/2 and
WT mice. Levels of brain CoQ, which in humans is predomi-
nantly CoQ10 and in rodents CoQ9, are affected by nutrition
[40], thus the concentrations we observed in the brain may reflect
the physiologically normal level of the compound when nutrition is
adequate. If the level falls below this concentration, dietary
supplements can be used to increase it, as achieved in Smith et al’s
study who found decreased basal levels in brain CoQ10 in R6/2
mice as compared to WT controls [14]. Indeed, it has been
suggested that it is only possible to increase CoQ10 levels in brain
Table 1. Mean plasma and brain levels of CoQ10, in 10-week old mice, after 6 w of treatment.
Experiment Plasma (mg/ml)6SEM Brain (mg/g)6SEM
WT R6/2 WT R6/2
Female Male Female Male Female Male Female Male
2 vehicle 0.0360.01 0.0260.01 0.0460.01 0.0860.01 10.760.4 10.760.2 11.960.7 12.160.6
0.6% 1.360.3 0.560.8 1.660.1 1.060.2 13.2+1.6 14.0+1.5 14.2+0.3 13.7+0.5
Plasma: Both R6/2 and WT treated mice had higher levels than untreated mice. Treatment main effect: F(1,16) = 173.5, p,0.0001). Treated, but not untreated, mutant
mice had higher plasma levels than WT mice (genotype main effect: F(1,16) = 6.1, p,0.026; genotype6treatment interaction: F(1,16) = 6.0, p,0.02, simple main effects:
p,0.05). Levels were higher in females than male mice (gender main effect: F(1,16) = 15.7, ps,0.02). Brain: CoQ10 levels in animals receiving 0.6% CoQ10 were higher
than those of untreated mice, independent of gender and genotype (treatment main effect: F(1,16) = 15.8, p,0.01).
doi:10.1371/journal.pone.0009793.t001
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when there is a prior deficiency [41]. Consistently, although
unexpectedly, the concentrations of CoQ measured in this study
did not show a deficiency in the untreated R6/2 mice.
We designed our drug screening system to reduce non-specific
health problems, such as suboptimal nutrition due to progressively
reduced access to food as the motor dysfunction becomes critical
serious [29]. These health issues are secondary to the core HD
symptoms and not particularly enticing as functional endpoints for
drug discovery. For example, we used lowered waterspouts and
delivered food on the floor to enhance nutrient access and thereby
reduce the identification of compounds that non-specifically
ameliorate malnutrition. These measures are likely to help ensure
appropriate nutrition of all mice, including those with motor
deficits. On the other hand, HD pathology has been shown to be
present even under a well-controlled diet [42] and maybe due to
hypothalamic dysfunction [43] and not to nutritional factors, and
therefore optimized nutrition, as used in this study could better
mimic the human situation.
In this study, animals were housed in an enriched housing
environment with the addition of play tunnels, shredded paper
Figure 3. Effect of daily i.p. administration of 5mg/kg of minocycline in R6/2 mice. WT and R6/2 mice received either 5mg/kg of
minocycline or its vehicle by intraperitoneal injection. Minocycline had no effects on survival (A) on either R6/2 or WT mice, but transiently increased
the body weight (B) of mutant male mice at 8, 10, 11 and 12 weeks of age (treatment6gender6age interaction: F(22,312) = 4.2, p,0.0001; simple
main effects: ps,0.05). In the WT group, minocycline did not produce significant effects in body weight. In the rotarod test (C), although there was a
triple interaction of treatment, age and day for R6/2 mice, simple main effects did not reveal a consistent pattern (overall effects: treatment6age6day
interaction: F(10,143) = 3.2, p,0.001). There were no effects for the WT mice. Minocycline transiently increased locomotion (D) in R6/2 male mice
(treatment6gender6age: F(6,87) = 4.5; p,0.0005; simple main effects: ps,0.05 at 4 weeks of age) but decreased locomotion in the male WT mice
(treatment6gender6week interaction, F(6,102) = 2.6, p,0.03, simple main effects and post hocs, ps,0.05 at 4 weeks of age). Rearing frequency (E)
was transiently decreased by minocycline in female R6/2 mice at 6 weeks, but increased in male R6/2 mice at 6 and 8 weeks of age
(treatment6gender interaction: F(1,33) = 11.2, p,0.002; treatment6age interaction: F(3,87) = 6.4, p,0.001; treatment6gender6age interaction:
F(6,87) = 5.4, p,0.0001; simple main effects: ps,0.05). Minocycline decreased rearing in WT mice at 8 and 12 weeks of age especially in the male
group (treatment6gender interaction, F(1,37) = 9.9, p,0.0005; treatment6age interaction: F(3,102) = 8.9, p,0.0001, simple main effects, ps,0.05).
Minocycline did not affect grip strength (F) or rearing (G) in either R6/2 or WT mice although the latter showed a tendency to rear less (p,.07).
doi:10.1371/journal.pone.0009793.g003
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and a plastic bone to each cage. Standard housing conditions in
US labs typically lack the range of stimuli rodents are normally
exposed to in their natural habitats [44]. It is possible that
environmental enrichment may confound mouse trials by
increasing the heterogeneity of the clinical and neuropathological
phenotype [14]. However, if shown empirically that enrichment
increases heterogeneity, studies can then be powered appropri-
ately, as done in the studies reported here.
The more relevant question is therefore, whether studying mice
in a standard, non-enriched generates false positives by augment-
ing the chance of therapeutic effects secondary to HD pathology.
Housing conditions alone improve motor performance and weight
retention in several mouse models of HD [17,45,46] affecting the
levels of several brain proteins [47], brain volume [45], and
hippocampal neurogenesis [48]. For example, Schilling and
colleagues have consistently showed a beneficial effect of
enrichment in the HD-N171-82Q, which is comparable to that
obtained with CoQ at 11 weeks of age [17]. Although those
experiments were not designed with this comparison as a goal, this
view is consistent with the suggestion that enriched husbandry
practices alone may improve energy balance in such a way that
putative beneficial treatment effects (e.g. due to CoQ10) are no
longer apparent.
In humans, CoQ10 was well tolerated and safe at doses up to
3 g/day [49]. A randomized placebo-controlled, double-blind trial
with a dose of 600 mg/day showed a statistically non-significant
trend toward slowing in total functional decline with some
secondary measures showing positive trends. i.e. functional
assessment checklist and few cognitive measures [50]. A phase
III clinical trial is currently ongoing to test efficacy of 2.4 g/day
(http://clinicaltrials.gov/; study NCT00608881). In addition,
CoQ10 analogues that can achieve higher levels of the drug in
brain should be evaluated in HD. Along those lines, EPI-743, a
bioisostere of CoQ10, was found to have beneficial effects in a
small clinical trial for Leigh Syndrome (presented by Guy Miller,
in the 5h Annual CHDI Therapeutic Conference, 2010).
Minocycline, dosage and toxicity
In our evaluation of minocycline, we observed that the low dose
(5 mg/kg i.p.) showed some transient, statistically significant effects
in drug treated R6/2 mice on body weight, locomotion and
rearing, consistent with Chen et al’s study, although the effects
were not comparable to those published in effect size and duration
[25]. In addition, we found that high doses of minocycline resulted
in toxic effects with no amelioration of the R6/2 phenotype,
consistent with Smith et al’s findings [26]. Our results extend the
published studies as we used an expanded behavioral testing
battery that includes measures of survival not available in Smith et
al. study because of animal-welfare regulations at King’s College,
London, UK.
Smith et al. studied huntingtin aggregation in an organotypic
culture and found that minocycline at 30 mM inhibited aggregate
formation. In the R6/2 mouse model, however, doses required to
achieve similar concentrations in the brain were toxic, therefore
lower doses were used (1 and 5 mg/ml in the drinking water) for
assessment, which resulted in a concentration of 12.2 mM of
minocycline in the R6/2 brain after 5 days of treatment, very
similar to the results in our study. Using this maximum tolerated
dose, Smith et al. showed neither significant behavioral benefits
nor a reduction of huntingtin aggregation [26]. Hersch and
colleagues [51] point out three main reasons why Smith et al. may
have failed to reproduce Chen et al’s positive findings. First, they
note that Smith et al.’s initial use of a high dose of minocycline
(10 mg/ml), which was later reduced to 5 mg/ml during the trial
due to toxicity, may have resulted in irreversible toxic effects. They
also point out that Smith et al.’s oral administration is not
comparable to their intraperitoneal injections—and questioned
Smith et al’s measurement of brain minocycline concentration
after a single injection as a valid means of estimating the
compound’s concentration, whereas Chen and colleagues’ study
involved repetitive dosing. Finally, Hersch and co-workers raised
concerns that Smith et al.’s results may have been compromised by
the stability of minocycline solutions, which were prepared weekly
rather than daily.
We also administered the 5 mg/kg dose using daily i.p. injection
as in Chen at al.’s study, and prepared solutions fresh daily. We
also ran all behavioral assays at least 3 hours after administration
of the injections to avoid acute effects associated with transient
high doses of the drug in plasma [38] and measure concentration
after chronic dosing. In our study, where minocycline was
formulated in the food, the preparation was made daily to
minimize problems due to compound stability.
There are, however, other key differences between the two
reported studies that could explain the different outcomes.
Differences in husbandry conditions and the particular type of
R6/2 mice (CAG repeats, in particular) could account for the
differing results. Smith et al. bred the R6/2 mice in-house, in an
enriched environment, and provided mice with wet mush food,
whereas Chen et al. received mice from Jackson Laboratories and
then housed the mice under non-enriched conditions without
supplementation with wet mush food [25,26]. Although the exact
CAG repeat numbers for the published studies are not published,
they are probably close to the 150 CAG reported for mice in Stack
et al. study and deposited at Jackson Laboratories by Dr. Bates
(Stack et al, Bates personal communication), and thus higher than
the numbers measured for the mice in this studies (,110–125).
Table 2. Mean plasma and brain levels of minocycline.
Experiment Dose Plasma (uM)6SEM Brain (uM)6SEM
WT R6/2 WT R6/2
3 5mg/kg 1.760.7 0.860.5 0.960.1 0.360.1
4 0.10%= 1 mg/ml 1.660.3 4.560.4 2.760.4 3.860.4
0.375%=5 mg/ml 2.460.5 7.561.2 8.160.4 12.560.7
Experiment 3. Both plasma and brain minocycline levels were higher in WT mice compared to R6/2 mice (Plasma: F(1,19) = 1.4, p,0.01; brain: genotype main effect:
F(1,10) = 19.6, p,0.002). Experiment 4. Brain and plasma concentrations of minocycline in R6/2 mice were significantly higher than in WT treated mice (Brain:
treatment6genotype main effect: F(1,16) = 7.67, p,0.02, simple main effects: p,0.0001; plasma: genotype main effect: F(1,17) = 27.89, p,0.03) in the two 0.375%
dosing groups.
doi:10.1371/journal.pone.0009793.t002
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Possibly, due to a combination of one of these factors but also due
to different ways to assess survival, the average lifetime reported of
R6/2 mice differed greatly to a point that the study results may not
be comparable. Chen et al. reported an average survival of 86
days. Whereas, Smith et al. did not determine average lifetimes,
but in the studies reported here, using essentially the same
enriched husbandry conditions, we found that untreated R6/2
mice had an average lifetime of 10568 days (males) and 12367
days (females), in one cohort, and 109610 days (females) and
11367 days (males) in a second cohort. There were also clear
differences in the motor testing protocols. Chen et al. used a
constant speed (5 or 15 rpm) rotarod protocol whereas Smith et al.
(as in our study) used an accelerating rotarod, which may be a
more sensitive indicator of progression of disease motoric
dysfunction in the R6/2 mouse [52].
To determine if doses of minocycline higher that that used by
Chen et al. might be therapeutic we tested doses in the range as
reported by Smith et al. [26] but found them to be toxic,
consistently with several papers that reported minocycline toxicity
in R6/2 [26], the 3-NP model [28], in two models of PD [28,53]
Figure 4. Effect of the administration of 0.1% and 0.375% of minocycline in food in R6/2 mice. WT or R6/2 mice received either a normal
diet or a diet supplemented with minocycline (0.1% or 0.375%). Minocycline impaired survival in the R6/2 mice (A, ps,0.01) at both doses. 0.1%
minocycline transiently increased body weight (B) in male but not female R6/2 mice, whereas the 0.375% dose decreased body weight in both male
and female R6/2 mice (0.1% dose: treatment6age interaction: F(22,620) = 2.0, p,0.05; simple main effects: ps,0.03 at 7 to 11 weeks of age. 0.375%
dose: treatment6age6gender interaction: F(33,620) = 2.9, p,0.0001; simple main effects: ps,0.04 at 13, 14 and 15 weeks for female and 15 weeks
for male R6/2 mice). Minocycline did not affect WT mice body weight nor their rotarod (C) performance although the 0.375% dose briefly increased
latency to fall in R6/2 mice (treatment6age6day interaction: F(15,294) = 2.5, p,0.003; simple main effects: p,0.05 at 4 weeks of age only during the
3rd day of testing). The 0.375% dose slightly decreased locomotion (D) in the open field in treated R6/2 mice (treatment6age interaction:
F(6,179) = 3.96; p,0.002; treatment6age6session time: F(45,895) = 2.28, p,0.0001; simple main effects: ps,0.05 at 6 weeks (0–5 min), 8 weeks (5
and 15–20 min) and 12 weeks (10–15 min)) but did not affect the WT mice. The 0.1% dose of minocycline transiently increased rearing (E) in the R6/2
mice at 4 weeks of age but the 0.375% dose decreased rearing at 6 weeks of age (treatment6age interaction: F(6,179) = 2.9, p,0.015; simple main
effects: ps,0.04). The 0.375% dose also decreased rearing in male WT mice at 8 and 12 weeks of age (treatment6age: F(6,186) = 2.4, p,0.03;
treatment6gender6age: F(9,186) = 2.15, p,0.03; simple main effects: p,0.05). Neither dose affected grip strength (F) or climbing (G).
doi:10.1371/journal.pone.0009793.g004
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and in a model of hypoxic–ischemia [54]. The negative effects of
minocycline have been potentially linked to its inhibitory effects on
angiogenesis [55], or to it potential upregulation of prostaglandin 2
and COX-2 production [56], which could result in neuronal
injury rather than neuroprotection, although others have shown
reduction of such factors instead of upregulation [57].
In the R6/2 studies, we report here, the wild-type controls did not
show negative effects of minocycline, apart from decreasing
locomotor activity, suggesting that disease pathology may increase
sensitivity to possible side effects. Studies in humans have shown
little or no toxicity in the doses tested although minor to significant
toxic side effects have also been observed in humans including lupus
erythematosus-like syndrome, hepatitis, vestibular disturbance,
candida infection, gastrointestinal disturbance, urticaria and benign
intracranial hypertension [58,59,60,61,62,63,64,65,66,67]. Impor-
tantly, in two studies with ALS patients taking high doses of
minocycline -of up to 400 mg/day- observations of elevated hepatic
enzymes, faster deterioration in the ALS functional measures, and a
trend towards a faster decline in forced vital capacity and higher
mortality have been reported [68,69].
In HD patients, minocycline was studied in four clinical trials. A
small open-label trial of 100 mg/day showed improvement of
general motor and mini mental status exam measures after 6
months and amelioration of psychiatric symptoms and stabilization
of motor and neuropsychological function after 24 months [70,71].
Two other studies showed that 200 mg/day of minocycline was
well-tolerated, with no change in HD symptoms [72] although the
second study described negative effects in platelet count and an
increase in urea. Finally, a double-blind multicenter study, the
DOMINO study, did not show a meaningful slowing of the rate of
functional decline (http://www.movementdisorders.org/).
Standardization in preclinical studies
Several factors may contribute to the discrepancies among the
several preclinical studies. Colonies of R6/2 mice have been
established around the world, arising from two founder lines from
the Bates lab (Bates, personal communication). Despite their
common origin, the instability of the CAG repeats resulted in drifts
in CAG length in individual R6/2 colonies worldwide. It is clear
now that such differences account for a change in the onset and
severity of disease in the R6/2 mouse [73,74]. Thus, even
purchasing animals from major vendors may result in cohorts with
varying repeat lengths than those specified by the original vendor,
especially if colonies are established in the investigators’ labs and
breeders are not selected for a target standard CAG repeat
number. Indeed, major steps have been taken in the last few years
toward better control of CAG stability with the implementation of
high-resolution CAG sizing of Jackson Labs’ R6/2 colonies. In
addition, the CAG lengths for individual mice in preclinical studies
need to be measured and matched prior to treatment assignment,
to reduce rates of false positive or negative results, as there may be
imbalances of CAG sizes represented across drug and vehicle
control groups
In addition, the plasma levels of CoQ10 (0.6%) and brain and
plasma minocycline in R6/2 mice (0.375% dose) were higher than
in WT mice suggesting either higher food intake or differences in
PK. However, when 5 mg/kg minocycline was administered i.p.,
concentrations were lower, instead, in R6/2 mice. In one study,
food intake was slightly increased in young R6/2 mice,
consistently with increased our observed drug concentrations,
although it was decreased in older mice when clear motor deficits
became evident [75]. Thus, an explanation for the observed
differences in drug concentration needs further studies.
We also included large numbers of animals to meet minimal
power criterion as well as more behavioral assays, resulting in
comprehensive assessment. In addition to the commonly used
rotarod assay, we include measurements of distance traveled in the
open field, rearing and climbing behaviors. Our survival
measurements were not based on surrogate measures such a
prodding inactive mice [13,14,15,25], and may have resulted in a
more direct assessment of lifespan.
In addition to the sources of variability discussed above, biases
in the prediction of treatment efficacies are likely to exist due to the
overrepresentation of small studies reporting beneficial results.
Plots of the relationship between study quality (1/variance of
reported results) and effect size in the literature on amyotrophic
lateral sclerosis, for example, suggest that small, high variance
studies that yield positive results are common in the literature,
whereas those that yield negative results are nearly absent [76].
This type of bias is likely to pervade the health-related literature,
including that covering HD [77]. We suggest, as have others, that
there is a need to create a forum for the publication of preclinical
results, including negative studies, which will help view all
evidence leading to clinical trials [78,79].
With the preclinical and clinical evidence at hand, given the
safety profile of CoQ, the major problem associated with its use
seem to be of economic, given the high cost to the patient of the
available CoQ formulations and the expense of large clinical trials
powered for small treatment effects [50]. For minocycline, given
the frequency of adverse reactions in the healthy population and
the lack of robust therapeutic effects, it seems unwarranted to
continue testing normal doses (,200 mg/day) and unsafe to use
higher doses (,400 mg/kg) in patient populations.
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